Longevity clinic software specialist will discus

GARM Clinic announced that the inaugural Klotho L

Cognito Therapeutics will present new data at the

Lys Therapeutics, based in Lyon and Caen, France,

Amylyx will present data from its first-in-human,

The latest Longevity Show blog explores why heal

Series A funding will expand Re-Q and advance a

Partnership with SK Biopharma signals growing co

The company known for generating AI artwork want

New nanosensor could make gut health biomarkers

Next Health has opened its East Coast flagship at

Beyond Celiac Investments (BCI), the venture phil

Innovent Biologics has dosed the first patient in

Nura Bio completed a $73.

ReviveHealth announced a next-generation member p

Genflow Biosciences Plc has announced that Gad Be

For the price of a weekend trip, your genetic bl

New launch pairs Abbott’s over-the-counter con

New authority will regulate Dubai’s longevity

New approval for ultra-rare blood cancer highlig

As Canada approaches super-aged status, Manulife

Biogen has agreed to acquire RayThera Inc.

Scribe Therapeutics has been awarded more than $2

Insilico and SK Biopharmaceuticals have agreed a

Nuritas will exhibit plant-based peptide hydrolys

Beacon Biosignals participated in SLEEP 2026, eng

Greenstone Biosciences, Inc. and Intel Corp.

Positive Phase 1b results for ATX-304 suggest sc

Positive Phase 1b results for ATX-304 suggest sc

Phase 2 trial of leramistat targets sarcopenia,

Australian healthtech Everlab has raised $42 mil

New funding will support development of regenera

Stress-enduring cells offer a precision, homing-

Insilico Medicine announced completion of first-i

Oligomerix has received a $1.

Cambrian Bio presented Phase 1b human translation

NorthStrive Biosciences, a PMGC Holdings Inc.

Designs for Health launched Akkermansia Pro GLP-1

BPGbio presented clinical and translational findi

A once-daily patch could make one of pulmonary a

New data suggest MS 001 could help preserve musc

LNS8801 advances into the National Institute on

Dan DeBaun, founder of the largest authorized Be

A one-time CRISPR treatment dramatically reduced

Cognition Therapeutics announced on 16 June 2026

AlzeCure announced on 16 June 2026, that its Phas

Resolution Therapeutics has expanded its inflamma

ProJenX provided a development update for Proseti

Hangzhou Qihan Biotech announced that its off-the

Everlab has closed an oversubscribed AU$65 millio